Background: The aim of the study was to evaluate whether multiple sclerosis (MS) is associated with risk of cataract or glaucoma. Methods: We conducted a population-based cohort study utilizing the UK General Practice Research Database linked to the national hospital registry of England (1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008). Incident MS patients (5576 cases) were identified and each was matched to six patients without MS (controls) by age, gender, and practice. Cox proportional hazard models were used to estimate hazard ratios (HRs) of incident cataract and glaucoma in MS. Time-dependent adjustments were made for age, history of diseases and drug use. Results: MS patients had no overall increased risk of cataract, adjusted (adj.) HR 1.15 (95% CI 0.94-1.41) or glaucoma, adj. HR 1.02 (95% CI 0.78-1.33). Risk of cataract (adj. HR 2.45 (95% CI 1.56-3.86)) and glaucoma (adj. HR 1.70 (95% CI 1.01-2.86)) was significantly greater in patients < 50 years, particularly in men < 50 years: cataract, adj. HR 4.23 (95% CI 2.22-8.05) and glaucoma, adj. HR 2.76 (95% CI 1.28-5.93). Conclusion: This is the first study which showed that the risk of cataract and glaucoma is elevated in MS patients younger than 50 years, particularly men.
Introduction
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system characterized by gradual accumulation of focal plaques of demyelination in the brain. According to the World Health Organization report (2008), it affects more than 1.3 million people world wide, including 630,000 Europeans, 520,000 Americans and 66,000 Eastern Mediterranean patients. 1 Ophthalmological manifestations of MS such as optic neuritis, anterior and posterior uveitis, nystagmus and ocular motor involvements have been reported in epidemiological studies. Glaucoma (15%) and cataract (30%) were common in MS patients with symptomatic intraocular inflammation. 2 The rate of MS in patients with pars planitis has been reported to be higher (12-33%) than in the general population. 3, 4 Cataract is the leading cause of visual impairment in the world and poses a huge burden on the patient. It is characterized by a partial or total opacity of the crystalline intraocular lens. The risk of cataract or glaucoma may be increased in patients with MS due to shared mechanisms of disease processes, or as a consequence of glucocorticoid (GC) use. 5 Lens membrane functions are altered, resulting in cataract formation. 6, 7 Imam et al. measured a significantly increased activity of proteolytic enzymes in patients with MS during a relapse. 8 Other studies showed that cataracts are caused by intraocular inflammation of the uveal tract, [9] [10] [11] which can be a complication in patients with MS. 12 Risk of cataract and glaucoma in patients with multiple sclerosis 39 ,444 eligible patients (5, Glaucoma is a type of neuropathy marked by the loss of retinal nerve fibres resulting in visual field loss. The risk of glaucoma may be increased in patients with MS. Previous research has shown that macular thickness is reduced in patients with MS compared with controls. 13, 14 In mice, a loss of retinal ganglion cells during an optic neuritis secondary to the inflammatory process was reported. 15 In addition, it has been hypothesized that glaucoma neuropathy may be related to optic neuropathy, which can have various aetiologies including MS. 16 Not only MS itself, but also the use of high dosage systemic GCs may increase the risk of cataract. 17, 18 Treatment with short courses of intravenous methylprednisolone (500-1000 mg daily for 3-5 days), with or without a short prednisone taper, are commonly used in the treatment of relapses in patients with relapsing-remitting MS. 19, 20 Previous studies have shown that (long-term) use of GCs increases the risk of cataract. 17, 18 The interaction of the GC with the proteins of the lens results in an accumulation of granular material and vacuoles at the posterior pole of the intraocular lens. The combination of MS disease with cataract or glaucoma might even be of greater impact on these patients compared with those who suffer from one of the diseases, especially as most MS patients are of relatively young age. Because the relative risk of cataract or glaucoma in patients with MS as compared with population-based controls has not been studied, 3, 4, 21 the objective of our study was to evaluate whether MS increases the risk of cataract or glaucoma.
Methods

Data source
We conducted a population-based cohort study utilizing the United Kingdom (UK) General Practice Research Database (GPRD) that was linked to the national hospital statistics of England (HES). Linkage of GPRD and HES covered approximately 45% of practices between April 1997 and March 2008. The GPRD is a computerized database comprising the medical records of more than 10 million UK patients registered with a primary care physician. Previous epidemiological studies based on GPRD data have shown that it can be used to study patients with MS, 22 cataract, 23 and longitudinal exposure to oral GCs. 24, 25 Our study was approved by the Independent Scientific Advisory Committee (ISAC) of the Medicines and Healthcare Product Regulatory Agency (MHRA) of the United Kingdom, protocol number 09_098.
Study population
Eligible patients were aged 18 years and older and registered in GPRD between January 1987 and August 2009. All incident patients with at least one diagnosis of MS in either GPRD or HES were identified. They were matched with up to six control patients without a diagnosis of MS (convenient sample of large source population) by year of birth, gender and practice. The age-matching criterion was extended stepwise in 1-year increments to a maximum of 5 years when an exact age match was unavailable. The date of first diagnosis of MS in either GPRD or HES (index date) defined the start of follow-up. A control patient was assigned the index date of his matching MS patient. Patients were followed until the end of data collection, transfer out of practice or death, whichever came first. We divided the follow-up time of each individual patient into 30-day intervals until the end of follow-up or the outcome of interest (cataract or glaucoma). At the start of each interval, time-varying characteristics such as age, disease and drug history were determined. Figure 1 shows that the cohorts of MS patients and controls were slightly modified in the analysis to study cataract (A) and glaucoma (B). In analysis (A), all patients with a history of cataract before or on the start date of follow-up were excluded from MS patients and controls (sub-cohort I and II). In analysis (B), all patients with a history of glaucoma before or on the start date of follow-up were excluded from MS patients and controls (sub-cohorts III and IV).
Study outcomes
In sub-cohorts I and II, each patient was then followed for the occurrence of the first record of cataract. Cataract was classified according to the International Classification of Diseases (ICD-10) categories including ICD-10 categories H25.0-H28.8 and cataract extraction status ICD-10 category Z96.1 with the exception of congenital cataract. The corresponding Read codes were selected in GPRD. The first diagnosis of cataract in the computerized medical records in either GPRD or HES was taken as the event date of cataract.
In sub-cohorts III and IV, each patient was then followed for the occurrence of the first record of glaucoma, which was classified according to ICD-10 categories including categories H40.0-H42.8 or the first prescription of intraocular pressure-lowering therapy including topical miotics, beta-blockers, carbonic anhydrase inhibitors, sympathomimetics and prostaglandin analogues. The first diagnosis of glaucoma or initiation of anti-glaucoma therapy in the computerized medical records in either GPRD or HES was taken as the event date of glaucoma.
Statistical analysis
Cox proportional hazard models were used to estimate the hazard ratio (HR) of cataract and glaucoma in MS versus patients without MS. Kaplan-Meier curves were generated. With the exception of body mass index (BMI), smoking status and gender, risk factors were determined in a timedependent manner. All characteristics, except age, were treated as categorical variables. Each potential confounder was then added individually to the age and gender-adjusted HR. A change of 1% or more from the age and genderadjusted HR was considered significant and the confounder was added to the model.
In the evaluation of cataract risk in MS (analysis A) we adjusted our analyses for the use of systemic GCs, hypnotics/ anxiolytics, anticonvulsants and antidepressants 6 months prior to the start of a period. Furthermore, we adjusted our analyses for age, gender, smoking status, BMI and a history of diseases such as diabetes mellitus, chronic obstructive pulmonary disease, cerebrovascular disease, epilepsy, and ocular surgery.
In the analysis of glaucoma risk in MS (analysis B), we adjusted our analyses for the use of systemic GCs, anticonvulsants, serotonin-selective reuptake inhibitors, tricyclic antidepressants and ocular GCs 6 months prior to the start of a period. Furthermore, we adjusted our analyses for age, gender, smoking status, BMI and a history of diseases such as cerebrovascular disease, epilepsy, and uveitis.
Subgroup analysis was performed on age at index date. The age limit was set at 50 years based on the natural risk of cataract and glaucoma. Within these age categories we stratified by gender to detect possible differences.
Average daily dose and cumulative dose of systemic GC use was determined at the start of each period. The pivotal analysis was then stratified by daily and cumulative exposure to GCs. To analyze the use of oral and intravenous GCs during MS relapses, information on steroid exposure during MS relapses was retrieved from anonymized freetext. The Wald statistic was used to test statistical significant difference between all subgroups (and not only the reference group) by using 'test statements' in the PHREG procedure (SAS version 9.1.3). A p-value of 0.05 or smaller was considered statistically significant.
Sensitivity analysis
In order to study the impact of a potential misclassification of incident MS as prevalent cases (due to left censoring of the data) we conducted a sensitivity analysis. We restricted our pivotal analysis to those MS patients who had at least 12 months of valid follow-up time before the index date.
Results
A total number of 5576 incident MS patients and 33,868 matched controls were identified in GPRD and HES. Table  1 shows the baseline characteristics of both sub-cohorts. Exclusion of 540 patients with a history of cataract resulted in sub-cohorts I and II, while exclusion of 441 patients with a history of glaucoma resulted in sub-cohorts III and IV. In all sub-cohorts, the mean age of patients with MS and controls was 45 years and 70% were female. Compared with controls, patients with MS were more likely to smoke and to have a history of exposure to systemic GCs or antidepressants. Table 2 shows that in sub-cohorts I and II, 861 patients had a recording of cataract during follow-up. The overall risk of cataract in MS patients versus controls was not increased: adjusted (adj.) HR 1.15 (95% CI 0.94-1.41). However, the risk was significantly greater in MS patients who were aged < 50 years: adj. HR 2.45 (95% CI 1.56-3.86). The risk was increased more than four-fold in men < 50 years: adj. HR 4.23 (95% CI 2.22-8.05) as compared with all controls without MS. It was also statistically different from the risk in females with MS who were younger than 50 years of age: adj. HR 1.82 (95% CI 1.00-3.29). In the overall analysis, history of uveitis was not selected as a confounder because the 1% change was not reached. Nevertheless, we considered a history of uveitis as a Table 1 . Baseline characteristics of patients with incident multiple sclerosis and no history of cataract (sub-cohorts I and II) and no history of glaucoma (sub-cohorts III and IV).
Sub-cohorts I and II (Cataract analysis)
Sub-cohorts III and IV (Glaucoma analysis)
MS
No Figure 2a ), and MS patients exposed to systemic glucocorticoids at baseline were compared with unexposed MS patients (see Figure  2b ), for cataract and glaucoma. Table 3 shows that the risk of cataract was increased in MS patients who were exposed to anticonvulsants, adj. HR 1.68 (95%CI 1.13-2.51), when compared with patients without MS. It was also statistically different from the risk of cataract in MS patients who were not recently exposed to anticonvulsants. Compared with controls, the risk of cataract was increased in MS patients using statins, adj. HR 1.58 (95%CI 1.07-2.32), and systemic GCs, adj. HR 2.95 (95% CI 1.78-4.89), within the preceding 6 months. For both exposures, the risk was statistically different when comparing MS patients recently exposed versus not recently exposed to the medications. The risk of glaucoma was doubled in MS patients who had recently used systemic GCs (adj. HR 2.25 (95% CI 1.15-4.40)). Table 4 shows that the risk of cataract and glaucoma in MS patients was 2.5-3-fold increased in low-dose users of oral GCs (< 7.5 mg/day) when compared with the healthy control population, yielding adj. HR 3.28 (1.75-6.17) for cataract and adj. HR 2.76 (1.23-6.23) for glaucoma. There were no significant differences for the risk of both outcomes between MS patients who had been exposed to low (< 1 g prednisone equivalent) or high (> 5 g prednisone equivalent) cumulative doses of systemic GCs. MS patients on short-course GC treatment during MS relapse had a 3.5-4.4-fold increased risk of cataract or glaucoma when compared with the healthy control population, yielding adj. HR 3.55 (1.32-9.56) for cataract and adj. HR 4.58 (1.69-12.43) for glaucoma. In order to study the potential impact of misclassification of the diagnosis of MS, we restricted our analysis to patients who had a lead-in time of at least 12 months prior to their MS diagnosis. However, this did not change our results substantially. Taking in account a lead-in time of 12 months, the risk of cataract in MS patients was adj. HR 1.13 (95% CI 0.90-1.42), whereas it was 1.15 (95% CI 0.94-1.41) when no lead-in time was considered. Concerning glaucoma, the risk was adj. HR 1.06 (95% CI 0.79-1.41) with lead-in time considered versus adj. HR 1.02 (95% CI 0.78-1.33) when not accounting for a leadin time.
Discussion
This study showed that the risk of cataract and glaucoma in MS patients, as compared with healthy controls, was increased in those aged younger than 50 years and in particular in younger men. The risk of cataract and glaucoma was significantly increased in MS patients who had been exposed to systemic GCs during the past 6 months. In contrast, MS patients who were aged 50 or older did not have an increased risk of cataract or glaucoma when compared with a population-based sample without MS. The potential of MS to increase the risk of cataract may be explained by the actions of calpains (proteolytic enzymes) which have been reported to be involved in cellular processes and signal transduction. 26 Iman et al. measured a significantly increased calpain activity and expression in the peripheral blood mononuclear cells of MS patients during a relapse. 8 Calpain 1 (µ-calpain), the lens-specific isoenzyme Lp85, calpain 2 (m-calpain), calpain 3, calpain 10 and the lens-specific ) , anticonvulsants (unless stratified), serotonin-selective reuptake inhibitors, tricyclic antidepressants, ocular glucocorticoids (unless stratified) use 6 months prior, cerebrovascular disease, epilepsy and any uveitis ever before § : Statistically significant difference (p < 0.05) of the exposure to the medication versus non-exposure to the medication ¥ : Statistically significant difference (p < 0.05) of the exposure to the disease versus non-exposure to the disease isoenzyme Lp82 are known to be active in the lens, with calpain 2 being the most prevalent in mammalian cells. 6, 26 In the presence of elevated calcium ion (Ca 2+ ) levels, overactivation of calpains is thought to cause the degradation of lens proteins and changes in the cytoskeletal architecture. 6, 7, 26 These morphological and biological changes then result in the formation of cataract. Lower oestrogen levels in men versus women may explain why the risk in young men is increased compared with young women. In rodent studies, the risk of cataract was doubled in male rates, whereas female rats maintained a clear lens at a similar level of transforming growth factor beta (TGF-beta). 27 The relatively higher oestrogen levels in female rodents are considered to be protective against the cataractogenic influences of TGF-beta. 27, 28 Furthermore, hormone replacement therapy in humans has been associated with a protective effect in respect to cataract. 29 MS and glaucoma have both been associated with retinal nerve fibre layer (NFL) loss. Recent studies on macular region and NFL composition revealed a reduced thickness in both macular area as well as NFL thickness in MS patients compared with controls. 13, 14, 30 In addition, Bock et al. measured no difference in retinal NFL loss between MS patients and glaucoma patients. 30 However, it is unclear if there is a shared mechanism involved. Male gender is Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; N, number of cataract/glaucoma patients; IV, intravenous *analysis includes free-text information on oral and intravenous exposure during MS relapse # : referent: patients without multiple sclerosis; adjusted for age and gender, smoking, body mass index, hypnotics/anxiolytics, anticonvulsants, antidepressants use 6 months prior, diabetes mellitus, chronic obstructive pulmonary disease, cerebrovascular disease, epilepsy and any ocular surgery ever before & : referent: patients without multiple sclerosis; adjusted for age and gender, smoking, body mass index, anticonvulsants, serotonin-selective reuptake inhibitors, tricyclic antidepressants use 6 months prior, cerebrovascular disease, epilepsy and any uveitis ever before § : π: Statistically significant difference (p < 0.05) of the exposure to oral and intravenous glucocorticoids versus non-exposure to oral and IV glucocorticoids 6 months before ¥ : Statistically significant difference (p < 0.05) of the exposure to systemic glucocorticoids versus non-exposure to systemic glucocorticoids ever before π : Statistically significant difference (p < 0.05) of the exposure to oral and intravenous glucocorticoids versus non-exposure to oral and IV glucocorticoids 6 months before ξ : Statistically significant difference (p < 0.05) of the short-course exposure to oral and intravenous glucocorticoids versus non-short-.course exposure to oral and IV glucocorticoids in the year before φ : Statistically significant difference (p < 0.05) of the short-course exposure to oral glucocorticoids versus intravenous short-course exposure to glucocorticoids in the year before reported to be predictive for progression of glaucomatous disease. 31 In a population-based study from the Netherlands, it was found that male gender was a risk factor for developing glaucomatous visual field loss. 32 This is in line with our results of an elevated risk of glaucoma in younger males. The use of GCs has been associated with mainly posterior sub-capsular cataract (PSC) in population-based studies. 17, 33 Meanwhile, the exact pathway of GC-induced cataract is still unclear. Several mechanisms for the interaction of GC with lens tissue have been described. They involve activation of GC receptors which change gene transcription, disruption of epithelial cell proliferation and cell differentiation mechanisms. 5, 34 A recent study suggested that inadequate concentration of fibroblast growth factor 2 (FGF-2) in the posterior chamber inhibits lens fibre differentiation and causes epithelial cell proliferation and posterior migration instead. 5, 34 As a result, granular material and vacuoles accumulate at the posterior pole of the intraocular lens, an irreversible change of lens structure. 34, 35 Secondary or GC-induced glaucoma may be the result of altered aqueous outflow, which causes morphological and biological changes at the level of the trabecular meshwork. 36 As a consequence of this imbalance between aqueous production and outflow, intraocular pressure will rise. This may ultimately result in retinal nerve fibre loss. Biological evidence indicates that GC-induced cataract or NFL loss due to secondary glaucoma is irreversible. For this reason, we have evaluated the association between cumulative exposures to GCs in patients with MS. We found a non-significant but positive correlation between ever prior GC use and risk of glaucoma, and a statistically significant correlation between ever prior GC use and risk of cataract in patients with MS. The true relationship may have been stronger because we have not been able to measure patient exposure to GCs before enrolment in GPRD. We were able to evaluate detailed data on GC boosters that can be prescribed to MS patients with the relapsing-remitting type of the disease. There appears to be a trend of dose-dependent risk of cataract with cumulative GC use. However, our results should be evaluated with caution as the number of patients receiving this type of treatment was low.
In this study, we also found an increased risk of cataract in MS patients with recent anticonvulsant use. This is in line with case reports suggesting a link between anticonvulsant use and cataract. 37, 38 Punctate lenticular lesions have been reported with carbamazepine use. 37 However, we are not aware of any biological mechanism where anticonvulsants would cause cataract. The link noted may be due to the more frequent use of anticonvulsants in MS patients compared with the general population. In our study, we found an increased risk of cataract in statin users. Compared with controls, MS patients had more often been prescribed statins at baseline. A possible explanation is that during the study period, statins had been suggested to have neuroprotective properties. 39 Epidemiological studies that evaluated statin use and risk of cataract in a general population have shown conflicting results. [39] [40] [41] Some studies found either a protective effect 40 or no effect 41, 42 after adjustment. Before adjustment, Smeeth et al. did find a slightly increased risk of cataract, which disappeared after adjustment. 42 An increased risk of cataract and glaucoma in the younger MS population could also indicate a higher activity of the MS. The link may be due either to an intensified treatment regimen, or -if a causal relationship between MS and cataract and glaucoma exists -due to the MS disease. The available data did not allow us to establish the activity of MS disease at any time.
Our study has several strengths, including a reasonable sample size and that it was population based. Previous studies of GPRD data have shown a high level of data validity with respect to the reporting of MS, 22 cataract 43 and glaucoma. 44 Furthermore, we had detailed information on lifestyle parameters such as smoking and BMI, could determine longitudinal drug exposures, and we were able to link our data to the national hospitalization registry of England.
Our study also has several limitations. Diagnostic bias may be an alternative explanation for the 1.7-2.5-fold increased risk of ocular outcomes that we observed in younger patients with MS when compared with healthy controls. As compared with healthy controls, patients with MS are more likely to visit an eye specialist due to frequent ocular symptoms of MS such as double vision, ocular motor dysfunctions and optic neuritis (20%). This difference becomes more pronounced among younger patients. However, this does not explain why, in this study, the risk of cataract and glaucoma in younger men with MS was significantly increased compared with the risk of ocular outcomes in younger women with MS. Another limitation is that the registered date of MS diagnosis may not be the actual date of onset of the disease, as symptoms may arise several years before the ultimate diagnosis is made. For this reason, the early stages of the disease may be insufficiently represented in our study. We performed a sensitivity analysis with respect to the timing of the exposure but the links remained unchanged. Misclassification with regard to the outcome measures may play a role. We may have missed patients with early cataract or early glaucoma and considered them as disease free at the beginning of follow-up, or as disease free during follow-up. We would consider this as a non-differential potential misclassification of the outcome, which could have masked a true overall link between MS and cataract or glaucoma. In this study we had no information on important risk factors for cataract such as UV exposure as this is virtually impossible to measure in a population-based primary care setting. We were also unable to incorporate information on race and family history of glaucoma, known risk factors for the disease.
In conclusion, we found an increased risk of cataract and glaucoma in patients with MS aged younger than 50 years, particularly in men. In addition, we showed that the risk of cataract and glaucoma was increased in MS patients on systemic GC therapy. Our results suggest that patients with MS on systemic GC therapy, and especially males younger than 50 years, may benefit from ocular screening for cataract and glaucoma. Should further studies confirm our findings, then the financial feasibility of ocular screening should be determined.
